By Matt Grossman

 

Eli Lilly and Co. Tuesday narrowed its full-year revenue guidance and reiterated the same adjusted earnings forecast it had previously issued.

The Indianapolis-based pharmaceutical company said it now expects sales of $26.8 billion to $27.4 billion this year. It was previously forecasting sales of $26.6 billion to $27.6 billion.

Revenue from Covid-19 therapies in 2021 will likely be $1 billion to $1.1 billion, the company said.

Lilly's adjusted per-share earnings guidance was unchanged at $7.80 to $8 a share.

Analysts polled by FactSet have been forecasting adjusted earnings of $7.89 a share and sales of $27.21 billion.

 

Write to Matt Grossman at matt.grossman@wsj.com

 

(END) Dow Jones Newswires

August 03, 2021 07:06 ET (11:06 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Eli Lilly Charts.
Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Eli Lilly Charts.